Form 4: Supernus SVP, CMO Jonathan Rubin's Equity Changes

Supernus Pharmaceuticals' SVP, Chief Medical Officer Jonathan Rubin reported changes in his beneficial ownership of common stock and restricted stock units.

Summary

• Jonathan Rubin, SVP, Chief Medical Officer of Supernus Pharmaceuticals, Inc. (SUPN), reported changes in his beneficial ownership of common stock and derivative securities.
• On February 24, 2026, Mr. Rubin acquired a total of 3,125 shares of common stock through the vesting of Restricted Stock Units (RSUs) at a price of $0.00 per share.
• Concurrently, he disposed of a total of 1,643 shares of common stock to satisfy tax withholding requirements related to the RSU vesting. These dispositions occurred at prices of $51.35, $50.86, and $0.00.
• Following these transactions, Mr. Rubin's reported beneficial ownership of non-derivative common stock is 12,766 shares.
• Remaining derivative holdings include 3,375 Restricted Stock Units with vesting beginning February 19, 2026, and 2,500 Restricted Stock Units with vesting beginning February 22, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting routine executive compensation and continued equity ownership, without indicating any significant new corporate developments.

Positives

• The acquisition of 3,125 shares of common stock through RSU vesting indicates continued equity participation and alignment of interests by a key executive.
• The vesting of RSUs represents a successful milestone in the executive's long-term compensation plan.

Negatives

• Disposition of 1,643 shares for tax withholding reduces the executive's direct shareholding.
• One tax withholding disposition was reported at $0.00, which is an unusual reporting detail for a tax-related sale.

Future Outlook

Future vesting schedules indicate continued equity awards for the reporting person, with remaining Restricted Stock Units set to vest in installments beginning February 19, 2026, and February 22, 2025.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as RSU vesting and subsequent tax-related sales, are common in the pharmaceutical industry as part of executive compensation packages. These transactions typically reflect pre-scheduled equity awards rather than discretionary trading based on new material information.

Comparison to Industry Standards

• StockSavvy.ai observes that the structure of equity compensation, involving Restricted Stock Units that vest over several years, aligns with common practices in the biotechnology and pharmaceutical sectors. This approach aims to incentivize long-term executive retention and align management interests with shareholder value, similar to compensation plans seen at companies like Pfizer or Johnson & Johnson for their senior executives.

Stakeholder Impact

• Shareholders: Minimal direct impact, as these are routine compensation-related transactions. Indicates continued alignment of executive interests with company performance through equity ownership.

Next Steps

• Continued vesting of 3,375 Restricted Stock Units in four equal annual installments, beginning February 19, 2026.
• Continued vesting of 2,500 Restricted Stock Units in four equal annual installments, beginning February 22, 2025.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation transactions for a key executive, specifically the vesting of Restricted Stock Units and subsequent tax-related share dispositions. Such events are pre-scheduled and do not typically signal new material information about the company's operational performance or strategic direction. Therefore, the filing itself does not provide a basis for a change in investment recommendation, suggesting a 'hold' position is appropriate based solely on this information.

Keywords

Supernus Pharmaceuticals, SUPN, Jonathan Rubin, Insider Trading, Form 4, Restricted Stock Units, RSU Vesting, Equity Compensation, Beneficial Ownership, Chief Medical Officer